(주)셀렉스라이프사이언스

Technology

ILIAS is the Leader of Next-Generation Exosome Therapeutics.

Exo-Target® Exosome based Therapeutics

Exo-Target® is the therapeutic exosomes loaded with API molecule(‘target’ molecule) via ILIAS’s various platform technologies. Exo-Target® enables targeted delivery of API into the target cells by utilizing natural tropism of exosome producing cells and tissue targeting moieties displayed on the surface of exosome.

With our proprietary technology, ILIAS Biologics developed scalable exosome production system for Exo-Target® with high yield and purity

  • Cell Line Development We are working on variety of cell types to develop exosome producing cell bank in the perspective of high productivity, stability and target tissue·cell tropism.
  • In-vivo Study For safe and effective exosome therapeutics development, ILIAS Biologics conducts preclinical animal study either in our in-house animal facility or with our research collaborators who have relevant preclinical animal model in their laboratory.
  • Scientific Analysis ILIAS science team is continuously working on exosome analysis method development for the characterization and quality control of our exosome therapeutics, Exo-Target®.
  • Large Scale Manufacturing We successfully establish a large scale exosome production line in ILIAS Innovation Center, which allows us to produce Exo-Target® with the highest consistency in the yield and purity of exosome.

EXPLOR
Technology

Exo-Target

TOP

개인정보취급방침

닫기

이메일주소무단수집거부

닫기

사이트맵

사이트맵

몬트리올의정서
국내이행법령
사업안내
특정물질 수출입
알림·자료실
민원서비스
닫기